MX2021010475A - Diagnostico de esteatohepatitis no alcoholica. - Google Patents

Diagnostico de esteatohepatitis no alcoholica.

Info

Publication number
MX2021010475A
MX2021010475A MX2021010475A MX2021010475A MX2021010475A MX 2021010475 A MX2021010475 A MX 2021010475A MX 2021010475 A MX2021010475 A MX 2021010475A MX 2021010475 A MX2021010475 A MX 2021010475A MX 2021010475 A MX2021010475 A MX 2021010475A
Authority
MX
Mexico
Prior art keywords
alcoholic steatohepatitis
diagnosis
receiver
classifying
subject
Prior art date
Application number
MX2021010475A
Other languages
English (en)
Inventor
John Brozek
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2021010475A publication Critical patent/MX2021010475A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La presente invención se refiere a un método no invasivo para clasificar a un sujeto como receptor potencial o no receptor de un tratamiento para la esteatohepatitis no alcohólica.
MX2021010475A 2019-03-13 2020-03-12 Diagnostico de esteatohepatitis no alcoholica. MX2021010475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305305 2019-03-13
PCT/EP2020/056682 WO2020182952A1 (en) 2019-03-13 2020-03-12 Diagnosis of non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
MX2021010475A true MX2021010475A (es) 2021-10-01

Family

ID=66001139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010475A MX2021010475A (es) 2019-03-13 2020-03-12 Diagnostico de esteatohepatitis no alcoholica.

Country Status (9)

Country Link
US (1) US20220162702A1 (es)
EP (1) EP3938543A1 (es)
JP (1) JP2022524823A (es)
KR (1) KR20210138599A (es)
AU (1) AU2020236904A1 (es)
CA (1) CA3129339A1 (es)
MX (1) MX2021010475A (es)
TW (1) TW202100145A (es)
WO (1) WO2020182952A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021372802A1 (en) * 2020-10-30 2023-05-25 Genfit Methods of diagnostic of liver fibrosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2891347T3 (es) 2015-09-14 2022-01-27 Genfit Métodos para diagnosticar y evaluar la esteatohepatitis no alcohólica
AU2017242818B2 (en) 2016-03-30 2023-04-27 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
JP2020531023A (ja) * 2017-08-25 2020-11-05 ジェンフィットＧｅｎｆｉｔ 非アルコール性脂肪性肝疾患、非アルコール性脂肪性肝炎、及び／又は肝線維症の非侵襲的診断

Also Published As

Publication number Publication date
JP2022524823A (ja) 2022-05-10
US20220162702A1 (en) 2022-05-26
AU2020236904A1 (en) 2021-08-19
EP3938543A1 (en) 2022-01-19
TW202100145A (zh) 2021-01-01
WO2020182952A1 (en) 2020-09-17
KR20210138599A (ko) 2021-11-19
CA3129339A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
PH12018502057A1 (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MY165579A (en) Synthetic methods for spiro-oxindole compounds
TN2017000072A1 (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
PH12017501279A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
EP3700917A4 (en) NEW RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANARY ANTIGEN
MX2020002004A (es) Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica.
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2020007255A (es) Dispositivos portatiles para el monitoreo de la salud y metodos para construirlos y usarlos.
MX2020012107A (es) Composiciones y procedimientos para el tratamiento del cancer.
PH12019502694A1 (en) Anti-trkb antibodies
MX2021010475A (es) Diagnostico de esteatohepatitis no alcoholica.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
PH12017501872A1 (en) Methods of treating diseases
MX2018012061A (es) Inhibidor monovalente de la interaccion hutnfr1.
JOP20210339A1 (ar) أجسام مضادة لـ angpt2
PH12020500167A1 (en) Direct fed microbials for improving the general condition and health of fish
MX2021001393A (es) Composiciones para el tratamiento de la enfermedad de injerto contra huesped.
EP3586141B8 (en) Non-invasive diagnosis of fibrotic non-alcoholic steatohepatitis
EP4021570A4 (en) TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS